J. Pickup

Epidemiology · 2000–2004

A researcher in the Science corpus: 2 papers; trusts 4 researchers and is trusted by 4 researchers here, as inferred from the citation graph.

Subfields

Whom J. Pickup trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. J. Norrie
  2. Satoshi Uematsu
  3. S. Haffner
  4. P. Ridker
  5. M. Yuan
  6. Claudio Franceschi
  7. K. Esposito

Who trusts J. Pickup overall

  1. K. Wellen
  2. G. Hotamisligil
  3. B. Wajchenberg
  4. R. Jope
  5. B. K. Pedersen
  6. Nur Samsu
  7. O. Oguntibeju
  8. S. Melamed
  9. A. Steensberg

Papers from J. Pickup's perspective

Ordered by how strongly the researchers J. Pickup trusts endorse each paper. Same corpus, a different order for every researcher.

  1. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. (Journal of the American Medical Association (JAMA))
  2. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. (Diabetes)
  3. Reversal of Obesity- and Diet-Induced Insulin Resistance with Salicylates or Targeted Disruption of Ikkβ (Science)
  4. Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study (Circulation)
  5. Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells (Circulation)
  6. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). (Circulation)
  7. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. (Diabetes)
  8. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. (Diabetes)
  9. Toll-like receptors and innate immunity (Journal of molecular medicine)
  10. Adiponectin and development of type 2 diabetes in the Pima Indian population. (The Lancet)

Their papers